The UK Government's ambitious mass coronavirus testing plans could cost as much as £100 billion, according to reports.
In a conversation with Madhu Trehan, Eban talks about pharmaceutical regulations, institutionalised data forgery, perils of medical tourism, and attempts by Indian pharmaceutical executives to “game the system”.
Value-based drug pricing helps us to understand the maximum amount of money we're willing to pay for treatments that could benefit patients and save lives.
Americans pay more for prescription drugs than people in most other Western countries.
Macroeconomic pressures have hit the R&D returns of life sciences firms.